PCOS & Metabolic Therapies

Pioglitazone Hydrochloride (15 mg, 30 mg) is a thiazolidinedione (TZD) insulin sensitizer on the WHO Model List of Essential Medicines. It acts as a potent, selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptors, modulating the transcription of genes involved in glucose and lipid metabolism, substantially improving insulin sensitivity in skeletal muscle, liver, and adipose tissue, and preserving pancreatic beta-cell mass over time. Indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Acarbose (50 mg) is a microbial pseudotetrasaccharide competitive alpha-glucosidase and pancreatic alpha-amylase inhibitor on the WHO Model List of Essential Medicines. It retards digestion of complex starches and sucrose in the upper jejunum, shifting carbohydrate digestion to the lower bowel and blunting postprandial glycemic excursions. Indicated for type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Pioglitazone Hydrochloride (15 mg, 30 mg) is a thiazolidinedione (TZD) insulin sensitizer on the WHO Model List of Essential Medicines. It acts as a potent, selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptors, modulating the transcription of genes involved in glucose and lipid metabolism, substantially improving insulin sensitivity in skeletal muscle, liver, and adipose tissue, and preserving pancreatic beta-cell mass over time. Indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.

Orlistat Capsules 120 mg is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Acarbose (50 mg) is a microbial pseudotetrasaccharide competitive alpha-glucosidase and pancreatic alpha-amylase inhibitor on the WHO Model List of Essential Medicines. It retards digestion of complex starches and sucrose in the upper jejunum, shifting carbohydrate digestion to the lower bowel and blunting postprandial glycemic excursions. Indicated for type 2 diabetes mellitus.

Alpha-Ketoanalogue and Essential Amino Acids is an oral nutritional therapy for chronic kidney disease (CKD). It provides keto-analogues of essential amino acids that undergo transamination in the body, taking up amino groups from circulating urea nitrogen and converting into essential amino acids without generating new urea nitrogen, reducing uremic toxins and slowing the decline of GFR in pre-dialysis renal disease. Indicated for prevention and therapy of damages due to faulty or deficient protein metabolism in chronic kidney disease in connection with limited dietary protein intake (<= 40 g/day).

Imeglimin Hydrochloride (500 mg, 1000 mg) is a first-in-class oral tetrahydrotriazine derivative "glimin" antidiabetic agent. It targets mitochondrial bioenergetics across multiple organs: in the pancreas, it restores glucose-stimulated insulin secretion by increasing mitochondrial ATP and closing K_ATP channels while protecting beta cells against apoptosis; in the liver, it inhibits complex I of the respiratory chain, suppressing excessive gluconeogenesis; and in skeletal muscle, it enhances complex III activity, improving mitochondrial fatty acid oxidation and glucose uptake. Indicated for the treatment of type 2 diabetes mellitus as monotherapy or adjunct to other antidiabetic agents.

Imeglimin Hydrochloride (500 mg, 1000 mg) is a first-in-class oral tetrahydrotriazine derivative "glimin" antidiabetic agent. It targets mitochondrial bioenergetics across multiple organs: in the pancreas, it restores glucose-stimulated insulin secretion by increasing mitochondrial ATP and closing K_ATP channels while protecting beta cells against apoptosis; in the liver, it inhibits complex I of the respiratory chain, suppressing excessive gluconeogenesis; and in skeletal muscle, it enhances complex III activity, improving mitochondrial fatty acid oxidation and glucose uptake. Indicated for the treatment of type 2 diabetes mellitus as monotherapy or adjunct to other antidiabetic agents.

Lobeglitazone Sulfate Tablets 0.5mg is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Orlistat Capsules 60Mg is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.